Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
18 sept. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been accepted for oral presentation in a proffered paper session at the...
Aravive Announces Executive Management Transition Plan
08 août 2019 16h15 HE
|
Aravive, Inc.
HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Announces Participation at Wedbush PacGrow Healthcare Conference
08 août 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates
07 août 2019 16h05 HE
|
Aravive, Inc.
HOUSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
31 juil. 2019 07h05 HE
|
Aravive, Inc.
AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollment in Phase 1b Trial of...
Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
08 juil. 2019 07h05 HE
|
Aravive, Inc.
HOUSTON, July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Aravive) (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, announced that the independent Data Monitoring Committtee (DMC) has...
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
08 mai 2019 16h05 HE
|
Aravive, Inc.
HOUSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...